Sun Pharma Advanced Research Co Ltd has gained 99.05% in the last six months and 71.92% over the past one year, while trading at a P/E of 5.66, well below the industry average of 35. The rally has been supported by cost optimisation, clinical pipeline progress, a potential $100 million catalyst and higher FII ownership.